SCHEMBL21381827

SCHEMBL21381827

Cc1ccc(S(=O)(=O)ON2CC(c3ccc4c(c3)OCC4(C)C)C2)cc1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ VDR P11473 1/20 0.33
▸ DRD2 P14416 1/20 0.33
▸ DRD1 P21728 1/20 0.33
▸ DRD4 P21917 1/20 0.33
▸ DRD5 P21918 1/20 0.33
▸ DRD3 P35462 1/20 0.33
▸ CYP2D6 P10635 5/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ ALDH1A1 P00352 5/20 0.32
▸ CYP3A4 P08684 3/20 0.32
▸ CYP2C9 P11712 2/20 0.32
▸ CYP2C19 P33261 2/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ TRPM8 Q7Z2W7 1/20 0.32
▸ PTGS1 P23219 2/20 0.32
▸ PTGS2 P35354 2/20 0.32
▸ TSHR P16473 2/20 0.31
▸ RORC P51449 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21381802 0.77 VDR (0.40) VDRDRD2DRD1DRD4DRD5
SCHEMBL21381825 0.75 TRPM8 (0.34) CYP2D6ALDH1A1KDM4EHPGDTRPM8
SCHEMBL23148916 0.75 PKM (0.44) CYP2D6ALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL23091731 0.73 LMNA (0.49) VDRDRD2DRD1DRD4DRD5
SCHEMBL21381682 0.73 PDE4B (0.40) VDRDRD2DRD1DRD4DRD5
SCHEMBL21381893 0.72 VDR (0.36) VDRDRD2DRD1DRD4DRD5
SCHEMBL21381758 0.71 ALDH1A1 (0.44) VDRDRD2DRD1DRD4DRD5
SCHEMBL23150491 0.71 HSD11B1 (0.43) VDRCYP2D6CYP1A2ALDH1A1TSHR
SCHEMBL21381709 0.71 RARB (0.39) PTGS1PTGS2
SCHEMBL21381944 0.71 HSD11B1 (0.38) VDRCYP2D6CYP1A2ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 — — US disclosed
EP-3768684-B1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN LA ROCHE (CH) 2023-02-22 — — EP disclosed
US-20210107920-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2021-04-15 — — US disclosed
EP-3768684-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS F. Hoffmann-La Roche AG (CH) 2021-01-27 — — EP disclosed
WO-2019180185-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2019-09-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210107920-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC VDR 4529/4885DRD2 3496/4885DRD1 2379/4885
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC VDR 4529/4885DRD2 3496/4885DRD1 2379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback